<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36527522</PMID><DateCompleted><Year>2023</Year><Month>01</Month><Day>18</Day></DateCompleted><DateRevised><Year>2023</Year><Month>01</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1590-3478</ISSN><JournalIssue CitedMedium="Internet"><Volume>44</Volume><Issue>2</Issue><PubDate><Year>2023</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology</Title><ISOAbbreviation>Neurol Sci</ISOAbbreviation></Journal><ArticleTitle>A patient carrying a heterozygous p.Asn267Ser TARDBP missense mutation diagnosed as ALS and only involving lower motor neurons.</ArticleTitle><Pagination><StartPage>777</StartPage><EndPage>782</EndPage><MedlinePgn>777-782</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s10072-022-06555-1</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) is a rare neurodegenerative disease involving upper motor neurons (UMN) and lower motor neurons (LMN), which can be caused by mutations of pathogenic genes such as superoxide dismutase 1 (SOD1), sarcoma fusion (FUS), and TAR-DNA binding protein (TARBDP/TDP-43). Among these pathogenic genes, TARBDP mutation accounts for approximately 1% of sporadic ALS (sALS). The clinical phenotype of ALS is heterogeneous owing to different mutant genes and sites. Here, we report a case of sALS from China, the pathogenic site (c.800A&#x2009;&gt;&#x2009;G) of TARDBP in this patient was identified by whole-exome sequencing. But his clinical symptoms involve only the LMN, presented with progressive limb weakness, and dyspnea, without obvious limb muscle atrophy. We considered this patient as a possible LMN-dominant ALS variant and this report further explores the genotype-phenotype correlations of ALS10. Furthermore, interestingly, the pathogenic site in this person was previously reported in a Parkinson's disease (PD) patient and frontotemporal dementia (FTD) patient. Our findings illustrate the clinical heterogeneity and the types of diseases which carry p.Asn267Ser TDP-43 mutation were broadened furtherly. Meanwhile, considering that the range of neurodegenerative diseases associated with this mutant site may be expanding, the mechanism of different neurodegenerative changes mediated by the same pathogenic site still needs to be further studied.</AbstractText><CopyrightInformation>&#xa9; 2022. Fondazione Societ&#xe0; Italiana di Neurologia.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jin</LastName><ForeName>Shan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Neurology Department I, The First Affiliated Hospital of Anhui University of Chinese Medicine, Shushan District, No.117, Meishan Road, Hefei, 230000, Anhui, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Zhengzhe</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Anhui University of Traditional Chinese Medicine, Hefei, Anhui, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fang</LastName><ForeName>Xiang</ForeName><Initials>X</Initials><Identifier Source="ORCID">0000-0001-9716-8253</Identifier><AffiliationInfo><Affiliation>Neurology Department I, The First Affiliated Hospital of Anhui University of Chinese Medicine, Shushan District, No.117, Meishan Road, Hefei, 230000, Anhui, China. fxdxx@ahtcm.edu.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Huaizhen</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Neurology Department I, The First Affiliated Hospital of Anhui University of Chinese Medicine, Shushan District, No.117, Meishan Road, Hefei, 230000, Anhui, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Wenming</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Neurology Department I, The First Affiliated Hospital of Anhui University of Chinese Medicine, Shushan District, No.117, Meishan Road, Hefei, 230000, Anhui, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory of Xin'an Medicine Ministry of Education, Hefei, Anhui, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>KJ2019A0457</GrantID><Agency>Key projects of natural science research in Colleges and universities in Anhui Province</Agency><Country/></Grant><Grant><GrantID>2008085MH264</GrantID><Agency>General program of Anhui Natural Science Foundation</Agency><Country/></Grant><Grant><GrantID>2208085MH271</GrantID><Agency>General program of Anhui Natural Science Foundation</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>12</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>Italy</Country><MedlineTA>Neurol Sci</MedlineTA><NlmUniqueID>100959175</NlmUniqueID><ISSNLinking>1590-1874</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D000072105">Superoxide Dismutase-1</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020125" MajorTopicYN="N">Mutation, Missense</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="Y">Neurodegenerative Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072105" MajorTopicYN="N">Superoxide Dismutase-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ALS10</Keyword><Keyword MajorTopicYN="N">Clinical heterogeneity</Keyword><Keyword MajorTopicYN="N">Genotype&#x2013;phenotype correlation</Keyword><Keyword MajorTopicYN="N">TARDBP gene</Keyword><Keyword MajorTopicYN="N">Whole-exome sequencing</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>11</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>12</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>12</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>12</Month><Day>17</Day><Hour>11</Hour><Minute>15</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36527522</ArticleId><ArticleId IdType="doi">10.1007/s10072-022-06555-1</ArticleId><ArticleId IdType="pii">10.1007/s10072-022-06555-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kiernan MC, Vucic S, Talbot K et al (2021) Improving clinical trial outcomes in amyotrophic lateral sclerosis[J]. Nat Rev Neurol 17(2):104&#x2013;118. https://doi.org/10.1038/s41582-020-00434-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41582-020-00434-z</ArticleId></ArticleIdList></Reference><Reference><Citation>Brenner D, Freischmidt A (2022) Update on genetics of amyotrophic lateral sclerosis[J]. Curr Opin Neurol 35(5):672&#x2013;677. https://doi.org/10.1097/WCO.0000000000001093</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WCO.0000000000001093</ArticleId></ArticleIdList></Reference><Reference><Citation>S&#xe1;nchez-Tejerina D, Restrepo-Vera JL, Rovira-Moreno E et al (2022) An atypical presentation of upper motor neuron predominant juvenile amyotrophic lateral sclerosis associated with TARDBP gene: a case report and review of the literature[J]. Genes 13(8):1483. https://doi.org/10.3390/genes13081483</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/genes13081483</ArticleId></ArticleIdList></Reference><Reference><Citation>Rayaprolu S, Fujioka S, Traynor S et al (2013) TARDBP mutations in Parkinson&#x2019;s disease[J]. Parkinsonism Relat Disord 19(3):312&#x2013;315. https://doi.org/10.1016/j.parkreldis.2012.11.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.parkreldis.2012.11.003</ArticleId></ArticleIdList></Reference><Reference><Citation>Borroni B, Bonvicini C, Alberici A et al (2009) Mutation withinTARDBP leads to frontotemporal dementia without motor neuron disease[J]. Hum Mutat 30(11):E974&#x2013;E983. https://doi.org/10.1002/humu.21100</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/humu.21100</ArticleId></ArticleIdList></Reference><Reference><Citation>Narain P, Pandey A, Gupta S et al (2018) Targeted next-generation sequencing reveals novel and rare variants in Indian patients with amyotrophic lateral sclerosis[J]. Neurobiol Aging 71:265. e9-265. e14. https://doi.org/10.1016/j.neurobiolaging.2018.05.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2018.05.012</ArticleId></ArticleIdList></Reference><Reference><Citation>Abou Daya S, Mahfouz R (2018) Circulating tumor DNA, liquid biopsy, and next generation sequencing: a comprehensive technical and clinical applications review[J]. Meta Gene 17:192&#x2013;201. https://doi.org/10.1016/j.mgene.2018.06.013</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mgene.2018.06.013</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordeeva V, Sharova E, Babalyan K et al (2021) Benchmarking germline CNV calling tools from exome sequencing data[J]. Sci Rep 11(1):1&#x2013;11. https://doi.org/10.1038/s41598-021-93878-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-93878-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Poon KS (2021) In silico analysis of BRCA1 and BRCA2 missense variants and the relevance in molecular genetic testing[J]. Sci Rep 11(1):1&#x2013;8. https://doi.org/10.1038/s41598-021-88586-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-88586-w</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper&#x2010;Knock J, Julian T H, Feneberg E et al (2022) Atypical TDP&#x2010;43 protein expression in an ALS pedigree carrying a p. Y374X truncation mutation in TARDBP[J]. Brain Pathol e13104: 1&#x2013;12. https://doi.org/10.1111/bpa.13104</Citation></Reference><Reference><Citation>Tziortzouda P, Van Den Bosch L, Hirth F (2021) Triad of TDP43 control in neurodegeneration: autoregulation, localization and aggregation[J]. Nat Rev Neurosci 22(4):197&#x2013;208. https://doi.org/10.1038/s41583-021-00431-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41583-021-00431-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Fazal R, Boeynaems S, Swijsen A et al (2021) HDAC6 inhibition restores TDP&#x2010;43 pathology and axonal transport defects in human motor neurons with TARDBP mutations[J]. EMBO j 40(7):e106177. https://doi.org/10.15252/embj.2020106177</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embj.2020106177</ArticleId></ArticleIdList></Reference><Reference><Citation>Suk TR, Rousseaux MWC (2020) The role of TDP-43 mislocalization in amyotrophic lateral sclerosis[J]. Mol Neurodegener 15(1):1&#x2013;16</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-020-00397-1</ArticleId></ArticleIdList></Reference><Reference><Citation>de Boer EMJ, Orie VK, Williams T et al (2021) TDP-43 proteinopathies: a new wave of neurodegenerative diseases[J]. J Neurol Neurosurg Psychiatry 92(1):86&#x2013;95. https://doi.org/10.1136/jnnp-2020-322983</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2020-322983</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J, Liu Q, Sun X et al (2022) Genotype&#x2013;phenotype association of TARDBP mutations in Chinese patients with amyotrophic lateral sclerosis: a single-center study and systematic review of published literature[J]. J Neurol 1&#x2013;9. https://doi.org/10.1007/s00415-022-11042-w</Citation></Reference><Reference><Citation>Erazo D, Luna J, Preux PM et al (2022) Epidemiological and genetic features of amyotrophic lateral sclerosis in Latin America and the Caribbean: a systematic review[J]. Amyotroph Lateral Scler Frontotemporal Degener 23(1&#x2013;2):4&#x2013;15. https://doi.org/10.1080/21678421.2021.1909066</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2021.1909066</ArticleId></ArticleIdList></Reference><Reference><Citation>Roggenbuck J, Rich K A, Vicini L et al (2021) Amyotrophic lateral sclerosis genetic access program: paving the way for genetic characterization of ALS in the clinic[J]. Neurol Genet 7(5):1&#x2013;8.&#xa0; https://doi.org/10.1212/nxg.0000000000000615</Citation></Reference><Reference><Citation>Kj&#xe6;ldgaard AL, Pilely K, Olsen KS et al (2021) Prediction of survival in amyotrophic lateral sclerosis: a nationwide, Danish cohort study[J]. BMC Neurol 21(1):1&#x2013;8. https://doi.org/10.1186/s12883-021-02187-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12883-021-02187-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinto W, Naylor FGM, Chieia MAT et al (2019) New findings in facial-onset sensory and motor neuronopathy (FOSMN) syndrome[J]. Revue Neurol 175(4):238&#x2013;246. https://doi.org/10.1016/j.neurol.2018.04.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurol.2018.04.010</ArticleId></ArticleIdList></Reference><Reference><Citation>Connolly O, Le Gall L, McCluskey G et al (2020) A systematic review of genotype&#x2013;phenotype correlation across cohorts having causal mutations of different genes in ALS[J]. J personalized med 10(3):58. https://doi.org/10.3390/jpm10030058</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jpm10030058</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>